| Literature DB >> 7779250 |
Abstract
Cytokine-binding proteins (CBPs) block the ability of cytokines to interact with their receptors. These agents can potentially provide a means of treating pathological conditions that have a significant cytokine involvement. However, a major drawback of such approaches relates to the fact that CBPs stabilize the cytokine in the form of a cytokine-CBP complex in vivo. Here, Bernard Klein and Hervé Brailly discuss the possibility that CBPs behave either as agonists or antagonists according to their pharmacokinetic characteristics in vivo, and suggest a mechanism by which stable complexes might be cleared from the system.Mesh:
Substances:
Year: 1995 PMID: 7779250 DOI: 10.1016/0167-5699(95)80161-8
Source DB: PubMed Journal: Immunol Today ISSN: 0167-5699